(Q51828792)

13 April 2018

title

Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer? (English)

1 reference

13 April 2018

1 reference

Tien Le

1

1 reference

13 April 2018

Wylam Faught

series ordinal

2

1 reference

13 April 2018

Laura Hopkins

series ordinal

3

1 reference

13 April 2018

Michael Fung-Kee-Fung

series ordinal

4

1 reference

13 April 2018

publication date

1 January 2009

1 reference

13 April 2018

Journal of Obstetrics and Gynaecology Canada

published in

1 reference

13 April 2018

volume

31

1 reference

13 April 2018

issue

1

1 reference

13 April 2018

page(s)

42-47

1 reference

13 April 2018

Ovarian cancer: epidemiology, biology, and prognostic factors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Primary surgery for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1701-2163%2816%2934052-X

7 January 2021

10.1016/S1701-2163(16)34052-X

Identifiers

DOI

0 references

1 reference

13 April 2018